Stem Cell Clinic

Methods of Producing Thymic Emigrants from Induced …

By Induced Pluripotent Stem Cells

Hematopoietic and pluripotent stem cells can be differentiated into T cells with potential clinical utility. Current approaches for in vitro T cell production rely on Notch signaling and artificial mimicry of thymic selection. However, these approaches result in unconventional or phenotypically aberrant T cells; which may lead to unpredictable behavior in clinical use. Thus, there exists a need for improved methods of generating conventional T cells in vitro from stem cells. Researchers at the National Cancer Institute (NCI) have developed a novel method for the in vitro differentiation of induced pluripotent stem cells (iPSCs) into induced pluripotent stem cell thymic emigrant (iTE) cells. Cells produced by this method are functionally equivalent to natural nave CD8+ T cells. The approach utilizes improved fetal thymic organ culture methodology to mature progenitor cells into conventional T cells in the presence of extrinsic Notch signaling. Cell culture conditions further provide for positive and negative selection to ensure proper maturation. This method produces conventional T cells that are suitable for clinical applications such adoptive cell therapy.

The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize this method of generating nave T cells from iPSCs.

Image: A visual allegory of the generation of iPSC-derived thymic emigrants (in red). Photo credit: Michael J. Kruhlak, Experimental Transplantation and Immunology Branch (ETIB)

CCR News: https://ccr.cancer.gov/news/article/stem-cell-technology-rejuvenates-can...

Development Stage: Pre-clinical (in vivo)

Related Invention(s): E-133-2017

Inventors:

Raul Vizcardo (NCI)more inventions...

Nicholas Klemen (NCI)more inventions...

Nicholas Restifo (NCI)more inventions...

Intellectual Property: Application No. 62/433,591 Application No. PCT/US2017/065986 Publications:Vizcardo, R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system. PMID 29562175 Collaboration Opportunity: Licensing and research collaboration

Licensing Contact: John Hewes, Ph.D. Email: John.Hewes@nih.gov Phone: 240-276-5515

OTT Reference No: E-250-2016 Updated: Dec 14, 2018

Originally posted here:
Methods of Producing Thymic Emigrants from Induced ...

Global Induced Pluripotent Stem Cells Market Analysis (2018 …

By Induced Pluripotent Stem Cells

The Induced Pluripotent Stem Cells Market (2018 2023): Global Industry Analysis research publication offers readers with a comprehensive knowledge of the induced pluripotent stem cells market scenario in forthcoming years. This report guides through various segments of the global induced pluripotent stem cells market with market size status and forecast 2023. These segments are determined by sizing the market with induced pluripotent stem cells type, end-use segment, and geography. Furthermore, the report offers strategic perspectives on market growth factors such as drivers, restraints, induced pluripotent stem cells market demand and supplier opportunities, technological developments and how they will shape the induced pluripotent stem cells industry.

Market Summary: The main objective of the report is to track the market events such as product launches, induced pluripotent stem cells market ups and downs in terms of volume US$ (mn) and volume (units) from 2013 to 2023, various development activities related to induced pluripotent stem cells products, latest trends, and technologies used in this field. The first overview section of the report comprised with a definition of the global induced pluripotent stem cells market, classification and regional outlook of the market. The regional analysis being used in this report that specifies opportunities available and growth prospects of the global induced pluripotent stem cells market within the specified regions. It additionally provides information related to value chain with a curated list of raw materials suppliers, distributors, induced pluripotent stem cells manufacturers, technological solutions providers and end users of the induced pluripotent stem cells.

Free Sample of GlobalInduced Pluripotent Stem CellsMarket report fromhttps://market.biz/report/global-induced-pluripotent-stem-cells-market-2018-mr/237010/#requestforsample

Global Induced Pluripotent Stem Cells Market: Competitive Insights

The crucial section of the report describes the vendor landscape of the global induced pluripotent stem cells market, it includes the profile of leading market players currently operating in the market. The analysis provides information about their market revenues, products manufactured by them, induced pluripotent stem cells manufacturing process and plants, opportunities that are motivating these players and business strategies followed by them. The induced pluripotent stem cells report helps businesses compete better using this scale of reference, although planning their future developments to counter the movements of the other players and stay ahead in the competition.

List of Market Players Profiled in the Report

Segments Covered in the Global Induced Pluripotent Stem Cells Market Report

The research study examines forecasts revenue growth of induced pluripotent stem cells market at global, regional & country levels and provides inclusive insight on the market developments and opportunities available in various segments of the induced pluripotent stem cells market from 2013 to 2023. For the purpose of this study, report segmented the global market based on region, end-user, and induced pluripotent stem cells type. The market shares contributed by these segments are formulated to give the readers a 360-degree assessment of the global induced pluripotent stem cells market.

Do Inquiry About The Report Here:https://market.biz/report/global-induced-pluripotent-stem-cells-market-2018-mr/237010/#inquiry

What will you discover from induced pluripotent stem cells report?

A comprehensive analysis of current and future market demand for the induced pluripotent stem cells, covering six world regions, end-use industries, growing markets for the induced pluripotent stem cells.

The report employs a combination of primary and secondary research methods for segmenting and estimating quantitative facets of the global induced pluripotent stem cells market.

Exclusive research on established and emerging market players to get competitive advantage of the global induced pluripotent stem cells market.

Extensive analysis of the market drivers, restraints, review of latest trends and technologies used, market openings for the induced pluripotent stem cells.

Details of induced pluripotent stem cells market sizes and five-year forecasts, segmented by product type, end use segment, and region and country worldwide.

Post Views: 21

Continue reading here:
Global Induced Pluripotent Stem Cells Market Analysis (2018 ...

Human being induced pluripotent stem cells (hiPSCs) display …

By Induced Pluripotent Stem Cells

Human being induced pluripotent stem cells (hiPSCs) display great promise for obesity treatment as they represent an unlimited source of brown/brite adipose progenitors (BAPs). their differentiation at a higher level. Open in a separate window Number 1 Differentiation of hiPSC-BAPs in EGM adipogenic medium.hiPSC-BAPs were induced to undergo differentiation in a traditional adipogenic medium routinely useful for adult APs (Adult) or within the EGM adipogenic moderate (EGM). (a) Twenty-five times afterwards, multilocular adipocytes had been detectable beneath the microscope only once cells had been maintained within the EGM adipogenic moderate; bar range: 50m. (b) RNAs had been prepared and examined for adipocyte marker appearance. Beliefs are means??SEM. n?=?6. *means p? ?0.05 and **means p? ?0.01. The TGF pathway lately emerged as a crucial anti-adipogenic player with the activation of Smad 2/314,15,16. The powerful anti-adipogenic aftereffect of TGF1 was verified on adult-BAPs (Fig. S2B). Oddly enough, members from the TGF family members such as for example and had been expressed through the initial times of hiPSC-BAP differentiation (Fig. 2a). and appearance was down-regulated in differentiated hiPSC-BAPs set alongside the appearance amounts in undifferentiated cells, but continued to be at a rate sufficient to keep the Smad2/3 pathway energetic ((phosphoSmad, Fig. 2b). These data recommended that hiPSC-BAPs secreted bioactive TGF family that may lock hiPSC-BAP differentiation. In contract with this hypothesis, moderate conditioned by hiPSCs-BAPs shown a powerful anti-adipogenic influence on adult-BAP differentiation (Fig. S2). An ERK inhibitor (UO126 at 5?M) or even a p38MAPK inhibitor (SB203580 in 10?M) was struggling to change the anti-adipogenic aftereffect of Rabbit polyclonal to CREB1 hiPSCs-BAP conditioned moderate on adult-BAPs (not shown). On the other hand, the anti-adipogenic aftereffect of the conditioned-medium was inhibited with the addition of 5?M SB431542, an inhibitor from the TGF signalling pathway17. As proven in Fig. 2b, energetic Smad 2/3 pathway could possibly be inhibited PF-03394197 manufacture upon SB431542 addition through the 1st 4 days of hiPSC-BAP differentiation. Then, a dramatically increase in and manifestation was observed (Fig. 2c). Transient inhibition of the TGF pathway, during the 1st 3 days of differentiation only, was sufficient to promote differentiation (Fig. S3). Completely, these data underline the essential part of TGF pathway in switching off hiPSC-BAP differentiation. Open in a separate window Number 2 Anti-adipogenic activity secreted by hiPSC-BAPs was reversed by SB431542.(a) Expression of TGF family members in undifferentiated (day time 0) and differentiated hiPSC-BAPs. (b) Activated Smad2/3 in undifferentiated and differentiated hiPSC-BAPs in the absence or presence of 5?M of PF-03394197 manufacture SB431542. (c) hiPSC-BAPs were induced to undergo differentiation in EGM2 adipogenic medium in the absence or PF-03394197 manufacture presence of 5?M SB431542. Twenty-five days later, RNAs were prepared and analyzed for the indicated genes. PF-03394197 manufacture Ideals are means??SEM. n?=?4. *means p? ?0.05 and **means p? ?0.01. Recognition of extrinsic factors advertising hiPSCs-BAP differentiation The commercial EGM medium consists of IGF1, FGF2, VEGF, EGF, hydrocortisone and ascorbic acid with no info concerning their concentrations. We showed that FGF2, VEGF and IGF1 were dispensable for hiPSC-BAP differentiation. In contrast, hydrocortisone, ascorbic acid and EGF were required (Fig. S4A). Finally, traditional adipogenic factors supplemented with SB431542 (5?M) and defined concentrations of ascorbic acid (25.5?g/ml), hydrocortisone (4?g/ml) PF-03394197 manufacture and EGF (10?ng/ml), hereafter named defined hiPSC-adipogenic medium, dramatically enhanced adipocyte formation and manifestation of adipogenic markers in the protein level (Fig. 3a,b). The defined hiPSC-adipogenic medium supported differentiation at a level identical to that when cells were maintained in total EGM2 adipogenic medium (Fig. S4B). Except SB431542, none of these essential factors was able to inhibit Smad2/3 activation (Fig. S4C). Importantly, hiPSC-BAP adipocytes were then able to respond to insulin as phosphorylated forms of IRS1, AKT and Erk1/2 were upregulated upon acute insulin administration (Fig. 3c). hiPSC-BAP progenies were also able to respond to forskolin, a chemical mimicking -adrenergic activation, by increasing gene manifestation and lipolysis (Fig. 3d,e). Overall, these data showed that adipocytes generated from hiPSC-BAPs were responsive to an adrenergic stimulus and displayed an active insulin signaling pathway, the hallmark of functional brownish/brite adipocytes. Interestingly, mesenchymal cells originated from two additional hiPSC sources and.

View original post here:
Human being induced pluripotent stem cells (hiPSCs) display ...

Embryonic Stem Cell Research – rtlofneo.com

By Embryonic Stem Cells

Embryonic Stem Cell Research

is taking a five day old living human embryo, cutting him or her open and extracting embryonic stem cells from the inside, thus killing a living human embryo.

Most embryonic stem cells are derived from embryos that develop from eggs that have been fertilizedinvitroin a clinicand then donated for research purposes. To obtain embryonic stem cells, the early embryo has to be destroyed. This means destroying a human life.A human embryo is a human being in the embryonic stage, just as an infant is a human being in the infant stage.No medical cures have resulted in working with embryonic stem cells.

Adult stem cells (also referred to as non-embryonic stem cells) are present in adults, children, infants, placentas, umbilical cords, and cadavers. Obtaining stem cells from these sources does not result in certain harm to a human being. In contrast to research on embryonic stem cells,adult stem cell research has already resulted in numerous instances of actual clinical benefit to patients.

Another potential obstacle encountered by researchers engaging in embryonic stem cell research is the possibility that embryonic stem cells would not be immunologically compatible with patients and would therefore be rejected, much like a non-compatible kidney would be rejected. A proposed solution to this problem is to create an embryonic clone of a patient and subsequently destroy the clone in order to harvest his or her stem cells. Cloning for this purpose has been termed therapeutic cloningdespite the fact that the subject of the researchthe cloneis not healed but killed. No one should be free to pursue gain (financial, health-related, or otherwise) through immoral or unethical means such as the taking of innocent life. We must not sacrifice one class of human beings (the embryonic) to benefit another (those suffering from serious illness).

Original post:
Embryonic Stem Cell Research - rtlofneo.com

About Us – U.S. Stem Cell Clinic

By Stem Cell Clinic

Dr. Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapins list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, Dr. Comella made the list of Top 50 Functional and Integrative Medical Doctors/Scientists in the country by DrAxe.com, one of the most visited natural health websites in the world.

Dr. Comella has pioneered stem cell therapies from various sources including cord blood, bone marrow, muscle, and adipose. She led the team that gained the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. In addition to advanced cell culturing experience, Dr. Comella has managed the development, manufacturing, and quality systems of a variety of cellular products. She has developed a wide range of regenerative techniques and products that have now been successfully implemented into the clinic setting. Her professional experience includes positions in several companies including US Stem Cell, VetBiologics, Tulane University and Osiris Therapeutics. Dr. Comella progressed from research engineer at Osiris Therapeutics developing stem cell therapies for osteoarthritis to building and managing the stem cell laboratory at Tulane Universitys Center for Gene Therapy. She was the co-founder and Chief Executive Officer of Stemlogix, a regenerative medicine company focusing on veterinary medicine.

She is currently serving as the Chief Scientific Officer and board member of US Stem Cell, a publicly traded company focusing on the discovery, development, and commercialization of autologous cell therapies for the treatment of degenerative diseases. She has been responsible for the development and implementation of cell therapies in the clinic for a variety of different indications for more than 7000 patients. Hundreds of practitioners world-wide have provided stem cell treatments to their patients using her protocols. Dr. Comella has a PhD in Stem Cell Biology and holds both an MS and BS in Chemical Engineering.

See more here:
About Us - U.S. Stem Cell Clinic

Brandon Stem Cell Clinic

By Stem Cell Clinic

Umbilical cord cells are comprised of proteins, growth factors, and stem cells. Blood is collected from the umbilical cord and then purified to rid it from any factors that could cause your body to reject the treatment. One of our health care providers will inject the material from the treated cord blood into the damaged joint or joints. This allows the active compounds found in the cord cells to go to work instantly to begin to reduce inflammation and promote healthy cellular division and regeneration. Some of the active compounds at work include: VEGF (Vascular Endothelial Growth Factor), IL-LRA (Interleukin-1, a receptor antagonist, stem cell factors (SCF), FGF-2 (Fibroblast Growth Factor-2) and Transforming Growth Factor-beta (TGF-beta). Each individual compound has a slightly different function, but combined, give your joints the needed material needed to kick-start healthy cellular renewal and regeneration of your tissue. The injection changes the chemistry inside the joint, creating a healthier environment that encourages positive, healing changes to take place. You will experience a better blood supply to the regenerative area, a reduction in damaging chronic inflammation, and stimulation of healthy tissue growth all because of this simple, non-surgical injection at our Brandon Stem Cell Clinic. Our goal in this process is to provide an alternative to invasive surgical procedures or drug intervention to manage or reduce pain. Surgical procedures occasionally result in infection, scar tissue, and even amputation in extreme cases. Prescription drug abuse is also reaching epidemic levels in Brandon and the rest of the country. At Brandon Stem Cell, we are looking to use umbilical stem cells to promote healing in the body in a holistic, minimally invasive approach.

Continued here:
Brandon Stem Cell Clinic

Stem Cell of Atlanta Regenerative Stem Cell Therapy …

By Stem Cell Doctors

Dr. Brandy Brown, DNP, APRN, FNP-C

A professional FNP-C, with a love of nursing and a passion for helping people, Dr. Brandy Brown, DNP, APRN, FNP-C, is an effective APRN, business owner, consultant, and educator with 15+ years industry experience. She is also the President/CEO and Co-founder of non-profit, BLINGG. Owner of Extraordinary Nurses, LLC and Extraordinary Family Healthcare.

Brandy Brown, graduated at every degree level as she started out as a CNA at age 20. She currently possesses a AA and ASN Dr. Brown, was not satisfied until she reached her ultimate lifetime goal of FNP. She pursued her BSN, then onto Frontier Nursing University for her MSN as a Family Nurse Practitioner. In 2016, completed her Doctoral Program for her DNP (Doctorate of Nursing Practice), bringing her career level to the top in her field. She is intelligent, driven and demonstrates genuine compassion and advocacy, to deliver best-in-class patient care and patient services. Nursing often involves hectic and fast-paced environments where judgment, discretion and on-the-spot leadership are required. Dr. Brandy Brown is developing into a leader in nursing and in her community. She is a motivator to everyone she meets to grow and become an impact in their career, life, profession, and community.

Brandy is knowledgeable and has comprehensive experience in many areas of nursing including: Labor & Delivery, Pain Management, Nutrition, Anesthetics, OB/GYN, Wellness, Womens Health, Pain management with alternative treatment and Family Practice. Dr. Brown, is linking natural and medical options for her patients to manage or resolve diseases.

See original here:
Stem Cell of Atlanta Regenerative Stem Cell Therapy ...

South Texas Spinal Clinic: Orthopedic Surgeons: South Texas

By Stem Cell Doctors

The goal of the doctors, nurses, and staff at the South Texas Spinal Clinic is to provide the very best orthopedic care to the communities of San Antonio and South Texas. Through excellent communication and consistent interaction between the staff and patient, the care at each of the 12 locations of South Texas Spinal Clinic is both professional and compassionate.

The healthcare professionals at South Texas Spinal Clinic are thoroughly trained and educated in orthopedic medicine, spinal orthopedic medicine, physical medicine, and rehabilitation, allowing them to bring a combination of considerable experience and expertise to every patient.

The team at South Texas Spinal Clinic has extensive experience in treating almost every musculoskeletal and orthopedic issue. They specialize in both medical and surgical management of back and neck disorders or injuries, herniated discs resulting in arm or leg pain, scoliosis, traumatic bone fractures, total joint replacement, rotator cuff repair, sports medicine injuries, and repair of damaged cartilage and ligaments (to name just a few).

The surgeons use the latest state-of-the-art techniques to perform minimally invasive surgery, microendoscopic discectomy, interbody fusions, partial and total joint replacement, and arthroscopic sports medicine surgery of the knee and shoulder.

Outside of surgery, South Texas Spinal Clinic offers expert treatments for a range of musculoskeletal injuries, including ultrasound-guided epidural spinal injections, facet joint injections, electromyography, plasma-rich platelet therapy, and stem cell injections.

One of the keys to successfully treating musculoskeletal issues is physical therapy, which the clinics provide. This service is designed to improve mobility, strength, confidence and, perhaps most important, protect against future problems.

For the best in individualized and compassionate orthopedic care, partner with South Texas Spinal Clinics. To learn more, call or use the online scheduling tool to get started.

Read the rest here:
South Texas Spinal Clinic: Orthopedic Surgeons: South Texas

Stem Cell Therapy – Los Angeles, San Diego and San …

By Stem Cell Doctors

Select a Problem Area

If you have pain, we're here to help. Regenexx Procedures are patented stem cell and blood platelet procedures that are used to treat a wide range of joint and spine conditions.

Click a problem area to discover what Regenexx can do for you.

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from shoulder pain due to arthritis, rotator cuff and shoulder labrum tears, overuse injuries, and other degenerative conditions. Regenexx is also a viable alternative for those considering shoulder replacement surgery.

View Details About Shoulder Treatments

Commonly Treated Conditions:

Shoulder Procedure Video

Regenexx Procedures are advanced stem cell and blood platelet procedures for foot and ankle conditions. Before you consider ankle surgery, fusion or replacement, consider the worlds leading stem cell and prp injection treatments.

View Details About Foot & Ankle Treatments

Commonly Treated Conditions:

Ankle Procedure Video

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from pain or reduced range of motion due to basal joint / cmc arthritis, hand arthritis, or other injuries & conditions in the hand.

View Details About Hand & Wrist Treatments

Commonly Treated Conditions:

The Regenexx family of non-surgical stem cell and blood platelet procedures offer next-generation injection treatments for those who are suffering from knee pain or may be facing knee surgery or knee replacement due to common injuries, arthritis, overuse and other conditions.

View Details About Knee Treatments

Commonly Treated Conditions:

ACL Procedure Video In-Depth with Dr. John Schultz ACL Procedure Video

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from pain, inflammation or reduced range of motion due tocommon elbow injuries, arthritis and overuse conditions.

View Details About Elbow Treatments

Commonly Treated Conditions:

The Regenexx family of hip surgery alternatives are breakthrough, non-surgical stem-cell treatments for people suffering from hip pain due to common injuries, hip arthritis & other degenerative problems related to the hip joint.

View Details About Hip Treatments

Commonly Treated Conditions:

Hip Labrum Procedure Video Hip Avascular Necrosis Procedure Video

Regenexx has many non-surgical platelet and stem cell based procedures developed to help patients avoid spine surgery and high dose epidural steroid side effects. These procedures utilize the patients own natural growth factors or stem cells to treat bulging or herniated discs, degenerative conditions in the spine, and other back and neck conditions that cause pain.

View Details About Spine Treatments

Commonly Treated Conditions:

Intradiscal Procedure Video

Regenexx has many non-surgical platelet and stem cell based procedures developed to help patients avoid spine surgery and high dose epidural steroid side effects. These procedures utilize the patients own natural growth factors or stem cells to treat bulging or herniated discs, degenerative conditions in the spine, and other back and neck conditions that cause pain.

View Details About Spine Treatments

Commonly Treated Conditions:

Cervical Spine Video

Read more from the original source:
Stem Cell Therapy - Los Angeles, San Diego and San ...

Conditions and Diseases Treated | Adult Stem Cell Therapy

By Adult Stem Cells

As pioneers in the field, TruStem Cell Therapy provides evidence-based care customized to suit patient needs in a safe, effective manner. The discovery of stem cells opened a whole new understanding of how healing works in the human body. TruStem Cell Therapy uses that science to provide access to therapy for painful and debilitating conditions.

Adult stem cells are natural healers that have almost limitless capabilities. Emerging evidence shows that adult stem cells are able to create completely unrelated cells making them valuable assets in the fight to treat many diseases.

TruStem Cell Therapy provides access to the stem cell therapy and the bodys own healing resources as a therapy for life-changing illnesses. Stem cells have the ability to develop into different cell types and aid in repairing the damage done by illness. This means they work with your body to heal tissue, help manage pain and relieve symptoms.

Our board certified surgeons have access to the latest research and state-of-the-art equipment, allowing them to harvest stem cells effectively and efficiently utilizing the least-invasive methods available. The goal is to provide access to patient-centric care with therapy using stem cells, giving the power back to patients. At TruStem Cell Therapy, we specialize in conditions treated with stem cells, such as:

See the article here:
Conditions and Diseases Treated | Adult Stem Cell Therapy

→←